CGRP Antagonist Compound Structures for Efficacy and Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for migraine, particularly those targeting calcitonin gene-related peptide (CGRP) receptors, have limitations in efficacy and specificity, leading to a need for more effective CGRP receptor antagonists.
Innovation Solution
Development of novel compounds with a specific chemical structure, as defined by Formula (1), which act as CGRP receptor antagonists, potentially offering improved therapeutic outcomes for migraine and related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current CGRP receptor antagonist treatments are used, then migraine treatment is provided, but efficacy and specificity are limited
Solution Approach 1:
The patent modifies chemical parameters of CGRP receptor antagonist compounds by varying substituents at specific positions (R1, R2, R3 groups and A1, A2 ring systems) to optimize both efficacy and specificity. This involves changing chemical structure parameters to achieve better binding affinity and selectivity for the CGRP receptor while maintaining antagonist activity.
Solution Approach 2:
The invention creates composite molecular structures combining different chemical moieties (bicyclic or monocyclic ring systems A1 and A2, linker L, and various substituent groups) to form novel CGRP receptor antagonist compounds. These composite structures integrate multiple functional elements that work together to enhance both efficacy and specificity of receptor blockade.
2Reliability
If current CGRP receptor antagonist treatments are used, then migraine treatment is provided, but therapeutic outcomes are insufficient
Solution Approach 1:
The patent segments the CGRP receptor antagonist molecule into distinct functional modules: ring systems A1 and A2, linker L, and substituent groups R1, R2, and R3. This segmentation allows systematic optimization of each module's contribution to therapeutic outcome while managing overall molecular complexity through modular design principles.
Solution Approach 2:
The invention applies local quality by introducing specific substituent groups (halo, alkyl, etc.) at particular positions on the molecular structure. These localized modifications enhance therapeutic outcome by optimizing interactions with specific regions of the CGRP receptor binding site without requiring complete redesign of the entire molecule.
Data Source
AI summary
The disclosures herein relate to novel compounds of Formula (1); and salts thereof, wherein A1, A2, Q, X, R1, R2 and R3 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.